普雷尼索隆疗法加速药物诱导的严重肝损伤的恢复:一项前性随机对照研究
Fang-Jiao Song1, Hong-Ling Liu1, Ying Sun1
1Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100005, China.
ILIVER..
|July 10, 2025
概括
皮质类固醇治疗,特别是普得尼索隆,可以加速严重药物诱导性肝损伤 (SDILI) 的恢复. 虽然它改善了患者的康复率,但在本研究中,它没有显著影响六个月的整体存活率.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 药物诱导性肝损伤 (DILI) 是一种严重的药物不良反应,其发生率越来越高.
- 免疫激活和全身炎症是DILI进展的关键因素.
- 对于DILI的皮质类固醇的临床效用仍在争论中.
研究的目的:
- 调查皮质类固醇治疗在加快恢复和减少严重DILI (SDILI) 的死亡率方面的疗效.
- 评估普得尼索隆对SDILI解决和6个月生存率的影响.
主要方法:
- 一项前性,随机对照性研究,涉及SDILI患者的总 bilirubin.
- 患者随机分配,接受普得尼索隆或标准护理 (对照).
- 主要终点是SDILI分辨率 (bilirubin降低),次要终点是6个月的整体存活率.
主要成果:
- 普雷尼索隆组在第8天的SDILI解决率显著更高 (50.75%与26.47%,p=0.002).
- 在普得尼索隆和对照组之间没有观察到6个月整体存活时间的显著差异 (95.52%与91.18%,p=0.3).
- 所有观察到的死亡发生在那些在第8天没有达到SDILI解决的患者中.
结论:
- 普雷迪尼索隆疗法似乎可以加速药物诱导严重肝损伤的患者的康复过程.
- 可能需要进一步的研究来澄清皮质类固醇在改善SDILI的长期结果中的作用.
更多相关视频
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
208
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
208
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
275
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
275
01:29Chronic Pancreatitis II: Collaborative Care
131
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
131
01:16Hepatic Drug Excretion: Influencing Factors
231
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
231
01:26Nephrotic Syndrome II : Assessment and Medical Management
24
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
24
01:29Drugs for Treatment of Ulcerative Colitis in IBD
242
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
242